News
The day at a glance · 4 min read
Mood · Cautious
+35
Sentiment, −100 to +100
Regeneron Q3 Revenue
$5.12B+36.3%
Regeneron Q3 EPS Beat
$20.07+23.5%
Bristol Myers Q3 Revenue
$13.07B+6.9%
Key driverStrong Q3 earnings from biotechs offset by broader sector weakness as healthcare index declined 0.1%
Daily briefHealthcare· Money365.Market AI ·

Q3 Earnings Lift Biotech; M&A Activity Accelerates

Regeneron and Bristol Myers beat estimates as Merck divests CDMO unit to Lonza; Eli Lilly nears record highs on weight-loss demand

Big Pharma & Biotech Earnings

Bullish

AbbVie Q3 Revenue

$17.4B+10.3%
01REGN▲ +3.60%
Regeneron Pharmaceuticals (REGN) reported third-quarter revenue of $5.12 billion, up 36.3% year-on-year and ahead of Wall Street expectations. The biotech company's non-GAAP profit of $20.07 per share exceeded analysts' consensus estimates by 23.5%, driven by pipeline progress and core brand performance. Regeneron will present at upcoming investor conferences including the Jefferies Global Healthcare Conference in London on November 17 and the Evercore Healthcare Conference on December 1.
02BMY
Bristol Myers Squibb (BMY) delivered third-quarter revenue of $13.07 billion, up 6.9% year-on-year and beating Wall Street expectations. The biopharmaceutical company's non-GAAP profit of $1.35 per share came in 12.4% above analysts' consensus estimates, though pipeline advances were partially offset by margin pressure. The company expects full-year revenue of approximately $50 billion, close to analysts' estimates.
03ABBV▼ -2.05%
AbbVie (ABBV) met Wall Street revenue expectations in the third quarter with sales of $17.4 billion, up 10.3% year-on-year. The pharmaceutical company's non-GAAP profit of $3.82 per share exceeded analysts' consensus estimates by 1.3%, driven by immunology and neuroscience franchise growth. Analysts noted the company passes key quality investing filters but flagged ROIC methodology, high payout ratio, and weak liquidity as areas warranting scrutiny.

M&A and Corporate Developments

Neutral

Kenvue Acquisition Value

$49B
01MRK
Merck (MRK) announced plans to divest its contract development and manufacturing organization (CDMO) business to Lonza, a global CDMO. The transaction is designed to sharpen the focus of Merck's Life Science business sector and provide the CDMO business with a platform for its next phase of development. Merck's Life Science sector will continue to offer its broad portfolio of consumables, technologies, and services to pharmaceutical, biotechnology, and CDMO customers.
02JNJ
Kimberly-Clark has acquired Kenvue, formerly part of Johnson & Johnson (JNJ), in a transaction with an estimated enterprise value of approximately $49 billion. The deal represents one of the largest consumer health transactions in recent years, ahead of Kimberly-Clark's November 5 earnings report. Johnson & Johnson separately drew attention for new clinical analyses at the TCT 2026 symposium linking its Impella heart pumps to lower in-hospital and short-term mortality in high-risk coronary procedures.

Weight-Loss Drug Momentum

Bullish
01LLY
Eli Lilly (LLY) is approaching near-record highs as demand for its weight-loss drugs Zepbound and Mounjaro continues to accelerate. Morgan Stanley raised Eli Lilly's price target amid what analysts described as unprecedented demand for the company's GLP-1 therapies. The company also swept all seven categories in its sector on the Overall leaderboard of Extel's 2026 All-America Executive Team Survey, placing first for Best CEO, Best CFO, Best Investor Relations Professional, Best IR Program, Best ESG, Best Investor/Analyst Event, and Best Company Board.
02MRNA
Moderna (MRNA) has generated substantial returns this year and may still have room to rise, according to market analysis. The healthcare stock's performance has prompted discussion among investors about its potential to deliver further gains, though specific catalysts were not detailed.

Healthcare Insurance and Devices

Neutral

UNH ETF Inflows (Oct 29)

$35.0M
01UNH
UnitedHealth Group (UNH) drew attention following four days of net ETF buying, capped by $35.0 million in purchases on October 29, concentrated in large healthcare and blue-chip funds. Senator Elizabeth Warren is pushing to dismantle UnitedHealth Group, while a nonprofit investor education group moved in the opposite direction by naming the insurer its top undervalued pick for early 2027. Recent headlines surrounding the company range from solid third-quarter results to regulatory changes such as easing prior authorizations for pediatric care.
02ISRG
Intuitive Surgical (ISRG), the global technology leader in minimally invasive care and pioneer of robotic-assisted surgery, announced the appointment of Aaron Martin, President of Insurance at Humana, to its board of directors effective January 1, 2027. The company said Aaron Martin has spent his career building and scaling healthcare technology at the intersection where payers, providers, and patients converge.

Healthcare Market Overview

Bearish

NYSE Healthcare Index

-0.1%
TMO
01
Healthcare stocks eased in late afternoon trading, with the NYSE Healthcare Index declining 0.1% as the sector faced mixed performance across subsectors. Strong third-quarter earnings from biotechnology companies were offset by broader concerns about certain large-cap names.
02TMO▼ -2.06%
Thermo Fisher Scientific (TMO) was identified among S&P 500 stocks considered risky, with analysts noting that some companies in the index are weighed down by poor execution, weak financials, or structural headwinds.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy